FibroBiologics, Inc.
FBLG
$0.95
$0.022.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.96% | -20.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 95.68% | -48.59% | |||
| Operating Income | -95.68% | 48.59% | |||
| Income Before Tax | -54.13% | 43.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -54.13% | 43.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -54.13% | 43.86% | |||
| EBIT | -95.68% | 48.59% | |||
| EBITDA | -98.18% | 49.25% | |||
| EPS Basic | -17.07% | 59.82% | |||
| Normalized Basic EPS | -17.07% | 59.82% | |||
| EPS Diluted | -17.07% | 59.82% | |||
| Normalized Diluted EPS | -17.07% | 59.82% | |||
| Average Basic Shares Outstanding | -94.03% | 39.72% | |||
| Average Diluted Shares Outstanding | -94.03% | 39.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||